



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857  
Re: BayTril®

Docket No. 96E-0504

JAN 21 1997

Stephen G. Kunin  
Deputy Assistant Commissioner for  
• Patent Policy and Projects  
U.S. Patent and Trademark Office  
Box Pat. Ext. / Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 4,670,444 filed by Bayer Aktiengesellschaft under 35 U.S.C. § 156. The animal drug product claimed by the patent is BayTril® (enrofloxacin), New Animal Drug Application (NADA) No. 140-828.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use for food producing animals of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp. 1224 (E.D. Va. 1989), aff'd, 894 F. 2d 392 (Fed. Cir. 1990).

The NADA was approved on October 4, 1996, which makes the submission of the patent term extension application on December 3, 1996, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely,



Ronald L. Wilson  
Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs

cc: Kurt G. Briscoe  
Sprung Horn Kramer & Woods  
660 White Plains Road  
Tarrytown, NY 10591-5144